Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder caused by mutations in the survival motor neuron 1 gene (SMN1) significantly reducing SMN protein expression 1, 2 and resulting in the selective degeneration of lower a-motor neurons 3 . Clinically, patients with SMA 1 typically show symptoms at 6 months of age and die by age 2 (ref. 4) . The SMN2 gene is almost identical to SMN1 except that SMN2 has a single nucleotide difference that results in only 10% of the full-length protein being produced and high levels of a truncated, unstable protein lacking exon 7 (SMND7) 5 . However, patients with several copies of SMN2 produce more fulllength protein and have a less severe phenotype 6 . Although current model systems using worms, flies or mice have provided invaluable data concerning the genetic cause of SMA, the mechanisms of motor neuron death and potential drug therapies 7 , they have important limitations. For example, mice, flies and worms lack the SMN2 gene and thus animal models require complicated knockout and overexpression strategies [8] [9] [10] [11] [12] . As some therapies aim to target activation of endogenous SMN2 as a potential disease modifier, a human cellbased assay system would be very beneficial. Although SMA patient fibroblasts are available for study, fibroblasts do not show the same vulnerability as motor neurons, and the processing and functioning of the SMN protein probably has unique features in a neural context that is highly relevant for understanding disease mechanisms.
Induced pluripotent stem (iPS) cells, which show marked similarities to embryonic stem cells, can now be derived from human adult somatic tissues [13] [14] [15] [16] [17] , and recent studies have been successful in generating patientspecific iPS cells from a variety of diseases including amyotrophic lateral sclerosis, muscular dystrophy and Huntington's disease 18, 19 . None of these reports, however, has shown any disease-specific changes in cell survival or function. In the current study we successfully established iPS cells from a type 1 SMA patient and his unaffected mother, and showed that these cells retained the capacity to generate differentiated neural tissue and motor neurons while maintaining a lack of SMN1 expression and the disease phenotype of selective motor neuron death. These cells also responded to compounds known to increase SMN protein. Together, these results will allow disease modelling and drug screening for SMA in a far more relevant system 20 .
Characterization of iPS cells
We generated iPS cells from primary fibroblasts from a type 1 SMA patient and his unaffected mother after infection with lentiviral constructs encoding OCT4 (also known as POU5F1), SOX2, NANOG and LIN28 (ref. 16) (Supplementary Fig. 1 ). Two SMA clones (3.5 and 3.6) and one wild-type clone (4.2) propagated robustly when maintained on mouse embryonic fibroblasts. Quantitative PCR with reverse transcription (qRT-PCR), teratoma formation, DNA fingerprinting and microarray analysis all indicated that reprogramming of wild-type and SMA fibroblasts to a pluripotent state occurred, along with repression of the exogenously introduced genes (Fig. 1f-j , Supplementary Tables  1-3 and Supplementary Figs 2-4) . Only the 3.6 clone (iPS-SMA) and the 4.2 clone (iPS-WT; Fig. 1a -c) were used for further evaluation in this study. Both the iPS-SMA and iPS-WT cells grew at similar rates and maintained a normal karyotype for at least 12 weeks (Fig. 1d, e) .
Cells from SMA patients have significantly reduced levels of SMN transcripts that contain all 9 exons (full-length transcripts) due to loss of the SMN1 gene 1, 2 . To test whether the derivation of iPS cells affected SMN production, iPS and fibroblast SMN RNA was analysed. RT-PCR analysis showed that iPS-WT had comparable SMN levels to the wild-type fibroblasts (Fib-WT), whereas iPS-SMA had lower levels that were similar to the Fib-SMA cells (Fig. 2a) . As expected owing to the maintenance of SMN2 function in this disorder 1, 2 , transcripts for some full-length SMN and the alternatively spliced product lacking exon 7 (D7) were identified in all samples (Fig. 2a) . Furthermore, specific digestion of full-length bands produced the expected SMN2 cleavage products in all samples, confirming that SMN2 produces fulllength SMN in both the wild-type and SMA cells (Fig. 2b) . Intact SMN1 was detected only in the wild-type cells, thus verifying the absence of SMN1 in SMA cells and recapitulating SMA and carrier transcript patterns 21 ( Fig. 2b) . qRT-PCR further confirmed the significantly reduced level of full-length SMN transcript in SMA cells (32-39% reduced compared to wild-type, Fig. 2c ). These data are consistent with full-length SMN mRNA levels observed in SMA peripheral blood mononuclear cells 22 . Taken together, these data demonstrate that the generation of iPS cells does not alter the critical gene expression profiles or alternative splicing events of SMN1 and SMN2 in unaffected or disease-specific contexts.
Neuronal differentiation of iPS cells
To establish whether the lack of SMN1 may affect neuronal differentiation or survival in this new model, we next generated neurons and astrocytes from both iPS-SMA and iPS-WT cells ( Supplementary  Fig. 1 ). Traditional embryoid body formation was found to be very inefficient for neural differentiation from iPS cultures and so an alternate protocol was developed. The iPS cultures were first removed from their feeder layers and grown as floating iPS spheres in a defined media for a minimum of 2 weeks. These could be continually passaged using a chopping method that avoids losing cell-cell contact known to be important for maintaining both neural and embryonic stem cell proliferation 23, 24 . These cultures were then dissociated and plated onto laminin-coated coverslips. The iPS-SMA and iPS-WT spheres generated nestin-positive cells indicative of a neural stem cell phenotype 25 ( Fig. 3a, b) . On further differentiation, Tuj1-positive neurons and GFAP-positive astrocytes were also found ( Fig. 3c, d ). The iPS spheres were simple to expand, remarkably stable over time and maintained the ability to produce neural progeny for more than 20 passages.
As SMA adversely affects motor neurons, we next addressed whether the iPS cells could be lineage-restricted towards a motor neuron fate ( Supplementary Fig. 1 ). Basing our differentiation model on a previously published report using human embryonic stem cells 26 , iPS spheres were grown in a neural induction medium containing retinoic acid for 1 week, followed by a further week of retinoic acid and sonic hedgehog (SHH). Spheres were then seeded onto laminin-coated coverslips for another 2-6 weeks (totalling 4-8 weeks of differentiation), and grown in the presence of retinoic acid, SHH, cyclic AMP, ascorbic acid, glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor. One week after plating, long fine processes resembling neuronal axons were observed and neural-like cells were seen migrating out from the sphere. Both iPS-SMA and iPS-WT spheres generated cells that expressed the motor neuron transcription factors HOXB4, OLIG2, ISLET1 (also known as ISL1) and HB9 (refs 27, 28) during the differentiation process (Fig. 3e, f and Supplementary Fig. 5 ). The presumptive motor neurons were then immunostained with SMI-32 and choline acetyltransferase (ChAT), which are established markers for mature motor neurons 29 . Both SMI-32 and ChAT staining identified positive neurons in all cultures after 4 weeks of differentiation (Fig. 3e-h ). At this point there was no significant difference between the iPS-SMA and iPS-WT cultures in the number of motor neurons (12.6% 6 2.2 and 9.5% 6 2.4, respectively) or their size (641.0 mm 2 6 81.3 and 669.8 mm 2 6 59.1, respectively, Fig. 3k , l) suggesting that iPS-SMA cells are capable of generating motor neurons, which is similar to the human condition and mouse models in which functional motor neurons are generated at early developmental times 30 .
To develop the system further, we cultured the cells for another 2 weeks and again analysed motor neuron number and size. Notably, at this time the iPS-SMA cultures had significantly fewer motor neurons (4.3% 6 2.0) with a reduced size (383.1 mm 2 6 38.6) compared to the iPS-WT cultures (24.2% 6 4.0, 654.8 mm 2 6 32.6, Fig. 3k, l) . However, there was no difference in the number of total Tuj1-positive neurons in either iPS-WT or iPS-SMA cells at 6 weeks of differentiation (15.78% 6 2.9 and 15.55% 6 2.8, respectively), suggesting that there is a specific effect of the SMA phenotype on motor neurons. Taken together, these data show that iPS-SMA cells can produce similar numbers of neurons and motor neurons initially, but that the disease phenotype selectively hinders motor neuron production and/or increases motor neuron degeneration at later time points. Although synapses were not observed after 6 weeks of differentiation, by 8 weeks synapses were identified by punctate synapsin staining on iPS-WT SMI-32-positive motor neurons and non-motor neurons ( Fig. 3i and Supplementary Fig. 6 ), suggesting that pre-synaptic maturation of the neurons was occurring in this system. Notably, synapsin staining remained diffuse on the iPS-SMA SMI-32-positive motor neurons (Fig. 3j) , although some punctate synapsin staining was observed on SMI-32 negative cells (Fig. 3j) , again suggesting a specific motor neuron deficit in the SMA cultures.
Drug induced increase of SMN protein
Finally, we assessed whether SMN-inducing compounds could increase SMN levels in the iPS-SMA cellular context because this would be an important proof-of-principle for the further development of drug screens. SMN protein is found in both the cytoplasm and nuclear aggregate structures called gems, and the number of gems present is inversely correlated to disease severity 2 . We therefore assessed nuclear gem localization in iPS-SMA-and iPS-WT-derived neurons and astrocytes in the presence or absence of 1 mM valproic acid or 320 mM tobramycin: two compounds shown to increase SMN protein levels [31] [32] [33] . Using an antibody against SMN, untreated Fib-WT and iPS-WT cells showed an abundance of nuclear gems that characterize the normal distribution of this protein (Fig. 4a, c) . Both untreated Fib-SMA and iPS-SMA cells showed the expected lack of nuclear gems (Fig. 4b, d ) providing further support for reliable disease modelling using iPS-SMA cells. After 2 days of drug treatment, there was no significant increase in gem localization in treated (Fig. 4e, g, i) compared to untreated (Fig. 4c, i) iPS-WT cells. However, valproic acid and tobramycin significantly increased the number of gems in treated compared to untreated iPS-SMA cells (Fig. 4d, f, h, i) . We further verified this increase by examining SMN protein by western blot analysis. Two days after drug treatment, total SMN protein was far higher in iPS-WT cells than in iPS-SMA cells (Fig. 4j, k) , owing to the lack of SMN1 expression in the latter (Fig. 2b) . iPS-SMA cells treated with either valproic acid or tobramycin showed a significant 2-or 3-fold increase, respectively, in SMN protein levels compared to untreated iPS-SMA cells (Fig. 4j, k) . We are at present assessing gem formation in differentiating motor neurons and have shown that they can indeed be detected (Supplementary Fig. 7 ). Together these data suggest that iPS-SMA cells respond to drug treatment in a similar fashion to Fib-SMA cells and could be useful for new drug screening specifically on motor neurons in future studies.
Discussion
Previous efforts to understand the mechanisms of SMA in human tissues have relied on fibroblasts from patients or immortalized nonmotor neuron cell lines. However, one of the most fascinating aspects of the disease is that a ubiquitous loss of SMN protein from all cells in the body results in the specific degeneration of motor neurons. SMN has been shown to form complexes involved in the production of small nuclear RNA proteins that make up the splicesosome [34] [35] [36] . More recently, SMN has also been shown to traffic to neuronal processes of motor neurons and may have other important roles in motor axons yet to be fully determined 37, 38 . Using human motor neurons carrying ARTICLES the SMA phenotype generated from a virtually limitless source of iPS cells described here should help to clarify further this new role for SMN in disease initiation and progression. This is, to our knowledge, the first report to observe diseasespecific effects on human motor neuron survival and drug induced increases in protective proteins, thus validating that the iPS model can recapitulate at least some aspects of this genetically inherited disorder. Although the motor neurons generated in the current study show appropriate morphology, specific markers and synapsin staining, experiments are at present underway to more fully assess their function including electrophysiology and co-cultures with muscle fibres. More clones from this and other patient sources also need to be studied. These are important next steps to ensure that the reprogramming has not subtly affected the ability of the motor neurons to function normally. However, this new model should provide a unique platform for studies aimed at both understanding SMA disease mechanisms that lead to motor neuron dysfunction and death, and the potential discovery of new compounds to treat this devastating disorder. It also points to a future in which iPS technology could be used to better understand and develop treatments for several other genetically inherited diseases.
METHODS SUMMARY
Detailed methods are included in the Methods section. SMA and wild-type fibroblast cell lines were from Coriell Institute for Medical Research. Lentiviral infection of the fibroblasts and iPS cell culture was performed as described previously 16 . PCR was performed according to standard procedures using primers specific for OCT4, SOX2, NANOG, LIN28, HOXB4, SMN and GAPDH as published previously 16, 22 and shown in the Supplementary Information. Gene expression profiling, DNA fingerprinting and microarray analysis were performed following standard protocols. Neural induction was modified from previously published methods 26 , and immunological analyses were performed using standard protocols for nestin (Chemicon, 1:10,000), Tuj1 (Sigma, 1:5,000), GFAP (Dako, 1:1,000), OLIG2 (Santa Cruz, 1:1,000), HB9 (Hybrodoma bank, 1:100), ISLET1 (Hybrodoma bank, 1:100), ChAT (Chemicon, 1:250), SMI-32 (Covance, 1:500), SMN (4B7 (ref. 33), 1:10), and synapsin (Calbiochem, 1:250). Neuron counts and measurements were analysed using Metamorph software, and statistical calculations were performed using Prizm software.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
